Nurix Therapeutics, Inc.
NRIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001549595
In the last 90 days, Nurix Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 211 institutions reported holding it in 13F filings for Q2 2026, worth $2.84B in total; ARK Invest is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Nurix Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 174 | 1 | 172 | −1 |
| Shares | 65.0M | 6.82M | 67.9M | +9.69M (+16.7%) |
| Value | $1.36B | $142.3M | $1.53B | +$311.3M (+25.6%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (29)
Institutions that held Nurix Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
Sold out (30)
Institutions that held Nurix Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
Not filed for Q3 2024 yet (1)
Institutions that held Nurix Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 6,820,015 | $142.3M |